Katie Brighton
Scientific Copywriter
Katie joined Technology Networks in January 2022 after completing a bachelor’s degree in biochemistry and a master’s by research degree in molecular and cellular biology, both at the University of Leeds. They loved the breadth of scientific content covered in their undergraduate studies and wanted to share their passion for research through science communication. As a scientific copywriter, Katie assembles newsletters, writes promotional webinar copy, supports the publication’s in-house writers and produces scientific content.
Latest Content
Article
Unpicking the Molecular Mechanisms Behind Age-Related Memory Loss
Technology Networks had the pleasure of speaking to Professor Ann Massie about her research into understanding how system xc - affects age-related memory loss.
Industry Insight
Extending the Reach of Psychedelic Therapy With Psychoplastogens
Delix Therapeutics is developing non-hallucinogenic psychedelics for use as at-home medications for mental health conditions. To find out more, we spoke to the CEO, Mark Rus.
Industry Insight
The Impact of Funding on Longevity Research
To find out more about how early-stage funding could improve longevity research, we had the pleasure of speaking to Garri Zmudze, executive director of the Longevity Science Foundation.
Article
Re-Educating the Immune Response To Treat Type 1 Diabetes
CAR T-cell therapy is largely used to treat cancers, but here we explore how Dr. Leonardo Ferreira and his team are using CAR T-cell therapy to treat Type 1 diabetes.
Industry Insight
Treating C. diff Infection and More With Gut Microbiome Transplants
Technology Networks had the pleasure of speaking to Thomas Lendvay, CMO and co-founder of Tend about the current applications of gut microbiota transplants and how they could be used in future.
Podcast
Opinionated Science Episode 42: Caffeine for ADHD and Cancer-Sniffing Worms
In this episode of Opinionated Science, the team discusses a new advance that uses a microscopic worm to sniff out lung cancer, why caffeine is being investigated to treat ADHD and a stats study that may undermine an important area of neuroscience.
Industry Insight
Identifying Risk Factors for Long COVID With Single-Cell Proteomics
In this interview we speak to Sean Mackay, CEO of IsoPlexis, to discuss how single-cell functional proteomics have helped researchers understand the risk factors behind long COVID.
Industry Insight
Developing Chicken-Free Egg Whites
Cellular agriculture could provide a more sustainable way to meet the demand for eggs. We spoke to Maija Itkonen, CEO of Onego Bio, to find out more about their chicken-free egg white.
Industry Insight
Driving Progress in Personalized Cancer Therapy
Personalized medicine has the potential to change the cancer patient's journey by predicting how they will respond to different treatments. Technology Networks spoke to Dr. Ofer Sharon, CEO of OncoHost, to find out more!
Industry Insight
Exploiting Bacteriophage as a Diagnostic Tool
Technology Networks spoke to Dr. Tomas Richardson from PBD Biotech, to hear more about how bacteriophage can be used to diagnose tuberculosis in both humans and cattle.
Advertisement
